A forum for researchers, students and applicants in the field of cyclodextrin technology
Rafael Holdings, Inc. announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick
Cyclodextrins (CDs) and their polymers are gaining momentum as advanced drug delivery systems. A recent review (https://www.sciencedirect.com/science/article/pii/S2590257125000203) highlights their progress
Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX,
New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer’s
Merck Sharp and Dohme LLC. has received initial U.S. Approval: 2017 PREVYMIS™ (letermovir) injection, for intravenous use. In the first
Rafael Holdings and Cyclo Therapeutics on Thursday announced a merger agreement as they look to spur development of their Niemann-Pick
A randomized, double-blind controlled trial (NCT05986799) sponsored by Amway (China) was planned to start in August 2023 to study whether
Neuromuscular blocking agents (NMBAs) are commonly used in the practice of anesthesiology for skeletal muscle relaxation to facilitate tracheal intubation,
Niemann-Pick disease type C (NPC) is a rare, fatal, pan-ethnic, autosomal recessive lysosomal storage disease characterized by progressive major organ
ADV6209, a new formulation of midazolam with the addition of γ-cyclodextrin for oral use, has recently been licensed as the
